AI Article Synopsis
Article Abstract
To end the COVID-19 pandemic, a large part of the world must be immune to the virus by vaccination. Therefore, this study aimed to gauge intent to be vaccinated against COVID-19 among ordinary people and to identify attitudes towards vaccines and barriers for vaccine acceptance. The study population comprises 1880 people residing in different countries that answer a prepared questionnaire. The questionnaire topics are demographics, historical issues, participants' attitudes and beliefs regarding vaccines, concerns, and vaccine hesitancy. Attitudes and beliefs relating to vaccines in general, and the COVID-19 vaccine, were ascertained. Overall, 66.81% of the contributors would like to be vaccinated against COVID-19, while %33.19 did not intend to be vaccinated. Reasons for COVID-19 vaccine hesitancy included concern regarding vaccine side effects, fear of getting sick from the uptake of the vaccine, and the absence of accurate vaccine promotion news. Individuals with higher education believe that India (68.6%) produces the best vaccine ( <0.001), while healthcare workers think the Chinese vaccine (44.2%) is the best ( =0.020). Individuals with higher education have not been vaccinated, not be healthcare workers, and females were the most contributors to effective of the vaccine in reducing mortality from COVID-19 disease. Given the degree of hesitancy against COVID-19 vaccination, a multifaceted approach to facilitate vaccine uptake that includes vaccine education, behavioral change strategies, and health promotion, is paramount.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233680 | PMC |
| http://dx.doi.org/10.34172/hpp.2021.21 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immunogenicity and safety of SARS-CoV-2 recombinant protein vaccine (CHO cell) LYB001 as a heterologous booster following two- or three-dose inactivated COVID-19 vaccine in adults aged ≥18 years: interim results of a randomized, active-controlled, double-blinded, phase 3 trial.
Expert Rev Vaccines
December 2024
Guangzhou Patronus Biotech Co, Ltd, Guangzhou, China.
Background: LYB001 is a recombinant protein COVID-19 vaccine displaying a receptor-binding domain (RBD) in a highly immunogenic array on virus-like particles (VLPs). This study assessed the immunogenicity and safety of LYB001 as a booster.
Research Design And Methods: In this randomized, active-controlled, double-blinded, phase 3 trial, participants aged ≥18 years received a booster with LYB001 or ZF2001 (Recombinant COVID-19 Vaccine).
Real-world effectiveness and causal mediation study of BNT162b2 on long COVID risks in children and adolescents.
EClinicalMedicine
January 2025
Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Background: The impact of pre-infection vaccination on the risk of long COVID remains unclear in the pediatric population. We aim to assess the effectiveness of BNT162b2 on long COVID risks with various strains of the SARS-CoV-2 virus in children and adolescents, using comparative effectiveness methods. We further explore if such pre-infection vaccination can mitigate the risk of long COVID beyond its established protective benefits against SARS-CoV-2 infection using causal mediation analysis.
View Article and Find Full Text PDFSociopolitical antecedents influencing COVID-19 vaccine uptake in Pima County, Arizona.
Vaccine X
January 2025
Mel & Enid Zuckerman College of Public Health, University of Arizona, Tucson, United States of America.
Introduction: Vaccine hesitancy among marginalized populations particularly in the Hispanic community over the course of the COVID-19 pandemic has presented as a public health issue. This study examined the relationship between political affiliation and vaccination decisions of Hispanic adults in Pima County, Arizona.
Methods: Between January and October 2022, 623 participants completed surveys in English or Spanish after completing informed consent process.
Challenges and strategies for sustainable and resilient immunization systems in sub-Saharan Africa: A comprehensive scoping review.
Vaccine
December 2024
Access to Medicines Research Centre, Faculty of Economics and Business, KU Leuven, 3000 Leuven, Belgium.
Background: Immunization is pivotal for health-related sustainable development, necessitating resilient and sustainable immunization systems. This scoping review explores challenges and strategies for sustained vaccine uptake in the new Decade of Vaccines (2021-2030) within sub-Saharan Africa, encompassing routine and non-routine vaccines.
Methods: The review followed the Joanna Briggs Institute's methodology to examine English-language articles published from January 01, 2021, to May 29, 2023.
Impact on meningococcal disease of different vaccination strategies with 4CMenB and MenACWY-CRM197 in infants and adolescents in Argentina.
Vaccine
December 2024
GSK, Emerging Markets, Santiago, Chile.
Background: Invasive meningococcal disease (IMD) is a life-threatening disease, primarily affecting infants and children. Argentina introduced routine meningococcal vaccination in infants and adolescents in 2017, with MenACWY vaccination targeting serogroups A, C, W, and Y (current National Immunization Program [cNIP]). Serogroup B, more prevalent since 2015, became predominant in children.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!